Viagra Scripts Rebounding, Pfizer Says; Will “Recreational” Users Return?
Executive Summary
Pfizer's Viagra "Value Card" program is already driving a rebound in prescription market share, the company maintained during its April 20 earnings call
You may also be interested in...
Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension
Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra
Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension
Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra
Pfizer Sees 5% Growth In Second Half; Currency, Competition Hurt Sales
Pfizer's revised forecast for 2004 revenues indicates that the company expects sales growth of about 5% during the second half of the year